Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Tanaka M, Sakai T, Inoue R, Eguchi S, Majima Y, Abe M
Hepatogastroenterology. 1986 Jun;33(3):105-8.
Eleven cases with hypersplenism, one with liver cirrhosis and ten with hepatocellular carcinoma (HCC) associated with liver cirrhosis, underwent transcatheter partial splenic arterial embolization. In four of ten HCC cases, the spleen was accidentally infarcted during the procedure of transcatheter hepatic arterial embolization (TAE). The mean infarcted area of the spleen was 55.7%. An increase in the peripheral platelet count was particularly remarkable and continued over one year after the embolization. High fever and abdominal pain were observed in all cases. The fever was seen for 18.0 days and pain was noted for an average of 12.8 days after the embolization. Other adverse effects such as pleural effusion and ascites were transitorily observed. Splenic embolization is an effective supporting therapy for hypersplenism in patients with cirrhosis or HCC.
11例脾功能亢进患者、1例肝硬化患者和10例合并肝硬化的肝细胞癌（HCC）患者接受了经导管部分脾动脉栓塞术。在10例HCC患者中的4例，在经导管肝动脉栓塞术（TAE）过程中脾脏意外梗死。脾脏的平均梗死面积为55.7%。栓塞术后外周血小板计数显著增加，并持续超过一年。所有病例均观察到高热和腹痛。栓塞术后发热持续18.0天，疼痛平均持续12.8天。还短暂观察到其他不良反应，如胸腔积液和腹水。脾栓塞术是肝硬化或HCC患者脾功能亢进的一种有效支持治疗方法。
